On August 24, CSPC PHARMA rose 4.46% in regular trading, trading at HK$9.575, with turnover of HK$107 million. The rally was driven by a wave of target price upgrades from major international investment banks following the company's strong interim results.

After the company reported H1 revenue of RMB 18.59 billion (+40.1% YoY) and attributable profit of RMB 6.09 billion (+139.2% YoY), multiple brokerages issued bullish notes. UBS raised its target price to HK$11.80, reiterating a Buy rating citing long-term revenue prospects from frontier technology platforms. Goldman Sachs lifted its target to HK$12.56, maintaining Buy. Citi raised to HK$14, while Morgan Stanley upgraded to HK$12 with an Overweight rating, citing accelerated business development income. The strong results were primarily fueled by approximately RMB 5.7 billion in licensing fee revenue from multiple AstraZeneca collaborations, with Q2 finished drug sales growing 16% YoY, accelerating from 6% in Q1.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)